STATEMENT OF NEED
Psoriatic arthritis is a chronic inflammatory disorder that affects approximately 20% of patients with psoriasis. Symptoms, which include joint pain, stiffness, swelling, tendon and ligament tenderness, silvery or gray scaly patches, nail discoloration, and fatigue, usually manifest in flares and greatly impact patients’ quality of life (Kimak et al, 2023; Cleveland Clinic, 2023). Many patients are not diagnosed with psoriatic arthritis until later stages when lesions are irreversible. Screening for risk factors and early symptoms, in addition to incorporating novel imaging modalities and biomarkers, is crucial to making an early diagnosis and administering treatment that can prevent or delay the disease (Kimak et al, 2023). With numerous novel therapies in development, it is critical for members of the multidisciplinary team to remain up to date on emerging data in order to tailor treatment selection and sequencing. This Multidisciplinary Task Force will explore strategies for increasing early intervention and optimizing management of psoriatic arthritis. It features perspectives from Christopher Ritchlin, MD, MPH, Professor and Chief of the Division of Allergy, Immunology and Rheumatology at the University of Rochester Medical Center; Jennifer Soung, MD, Director of Clinical Research at Southern California Dermatology and Clinical Faculty at Harbor University of California, Los Angeles; Archie Franklin, MBA, Patient Advocate and Volunteer for the National Psoriasis Foundation; Saba Mohiuddin, PharmD, BCACP, Clinical Pharmacist at KabaFusion; and Melodie S. Young, MSN, A/GNP-C, Nurse Practitioner at Mindful Dermatology and Modern Research Associates.
TARGET AUDIENCE
Rheumatologists, dermatologists, primary care physicians, nurse practitioners, physician assistants/associates, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with psoriatic arthritis (PsA)
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Utilize knowledge of defining features, screening tools, and biomarkers to provide timely and accurate diagnosis of PsA
- Evaluate the safety and efficacy of novel PsA therapies
- Appraise strategies for tailoring treatment selection and sequencing to individual patients with PsA
- Assess methods to improve supportive care for patients with PsA
REGISTRATION
There is no fee to view this live presentation.
PROVIDED BY
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Christopher Ritchlin, MD, MPH, discloses that he has served on an advisory board or panel for Janssen and Novartis; that he has served as a consultant for AbbVie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Solarea, and UCB; and that he has received grants/research support from Janssen, Novartis, and UCB.
Jennifer Soung, MD, dislcoses that she has served on an advisory board or panel for AbbVie, Amgen, Coval Biopharma, Lilly; that she has served on a speaker's bureau for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Regeneron/Sanofi, and UCB; that she has served as a consultant for Arcutis, Bristol Myers Squibb, Novartis, Pfizer, and Regeneron/Sanofi; and that she has received grants/research support from AbbVie, Amgen, Arcutis, Aslan, Dermavant, Janssen, KoBio Labs, Lilly, Novartis, Pfizer, Regeneron/Sanofi, and UCB.
Archie Franklin, MBA, has no relevant financial relationships to disclose.
Saba Mohiuddin, PharmD, BCACP, has no relevant financial relationships to disclose.
Melodie S. Young, MSN, A/GNP-C, discloses that she has served on an advisory board or panel for Abbvie, Amgen, Arcutis, Dermavant, LilIy, Novartis, Takeda, and UCB; that she has served on a speaker's bureau for Amgen, Dermavant, Johnson & Johnson, Leo, Lilly, Sun, and UCB; and that she has received grants/research support from AbbVie, Alumis, Amgen, Aslan, Boehringer Ingelheim, Caratherapeutics, Incyte, Janssen, Lilly, Pfizer, Takeda, and UCB.
i3 Health has mitigated all relevant financial relationships.
UNAPPROVED USE DISCLOSURE
i3 Health requires CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
The information provided at this CME/NCPD/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
COMMERCIAL SUPPORT
This activity is supported by educational funding provided by Amgen.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.
Christopher Ritchlin, MD, MPH
Christopher Ritchlin, MD, MPH, is a Professor and Chief of the Division of Allergy, Immunology and Rheumatology at the University of Rochester Medical Center. He is also Director of the Clinical Immunology Research Unit, where he is the principal investigator of several clinical trials investigating biologic molecules in the treatment of psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. Dr. Ritchlin’s research focuses on understanding the mechanisms that underlie pathologic bone resorption and new bone formation in psoriatic and rheumatoid arthritis.
Jennifer Soung, MD
Jennifer Soung, MD, is the Director of Clinical Research at Southern California Dermatology and Clinical Faculty at Harbor University of California, Los Angeles. She is a board-certified dermatologist who specializes in treating chronic autoimmune skin conditions, with expertise in advanced therapies such as phototherapy, systemic medications, and biologics. Dr. Soung is a frequent speaker at professional conferences and has published numerous peer-reviewed journal articles.
Archie Franklin, MBA
Archie Franklin, MBA, is a Patient Advocate and Volunteer at the National Psoriasis Foundation. He is a plaque psoriasis patient who has been volunteering at the National Psoriasis Foundation since 1989 in a variety of roles, including as a Research Ambassador, an Honored Patient Speaker, Chair of the Indianapolis Walk to Cure Psoriasis, and participant in Capitol Hill Day. He is also a part-time consultant within the pharmaceutical industry, serving as a patient-focused ambassador and educator at dermatology events.
Saba Mohiuddin, PharmD, BCACP
Saba Mohiuddin, PharmD, BCACP, is a Clinical Pharmacist at KabaFusion. She completed her Ambulatory Care Pharmacy Residency at Louis Stokes VA Medical Center and has also been an Ambulatory Clinical Pharmacy Specialist in Rheumatology at the Cleveland Clinic. Dr. Mohiuddin specializes in rheumatology and chronic disease state pharmacy. In her current role, she assists in providing biologic medications to patients in the home infusion setting, including medication counseling, assessment of ongoing biologic therapy, and coordination with the home infusion team.
Melodie S. Young, MSN, A/GNP-C
Melodie S. Young, MSN, A/GNP-C, is a Nurse Practitioner at Mindful Dermatology and Modern Research Associates. Previously, she was the Director of the Psoriasis Center at Baylor University Medical Center She specializes in dermatology and has over 30 years of experience in clinical trials for psoriasis, atopic dermatitis, acne, rosacea, hair loss disorders, and skin infections. Ms. Young has published numerous articles in nursing and medical journals.
We look forward to you joining us on Tuesday, February 11th @ 7:00 PM EDT! CLICK HERE to set a reminder & save the date!
Save the date for this live discussion to:
- Utilize knowledge of defining features, screening tools, and biomarkers to provide timely and accurate diagnosis of PsA
- Evaluate the safety and efficacy of novel PsA therapies
- Appraise strategies for tailoring treatment selection and sequencing to individual patients with PsA
- Assess methods to improve supportive care for patients with PsA
Subscribe to the i3 Health Youtube Channel
